BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, Toye B, Beaudoin A, Frost EH, Gilca R. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365:1693-1703. [PMID: 22047560 DOI: 10.1056/nejmoa1012413] [Cited by in Crossref: 535] [Cited by in F6Publishing: 238] [Article Influence: 48.6] [Reference Citation Analysis]
Number Citing Articles
1 Vincent C, Mehrotra S, Loo VG, Dewar K, Manges AR. Excretion of Host DNA in Feces Is Associated with Risk of Clostridium difficile Infection. J Immunol Res 2015;2015:246203. [PMID: 26090486 DOI: 10.1155/2015/246203] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
2 Zacharioudakis IM, Zervou FN, Pliakos EE, Ziakas PD, Mylonakis E. Colonization With Toxinogenic C. difficile Upon Hospital Admission, and Risk of Infection: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology 2015;110:381-90. [DOI: 10.1038/ajg.2015.22] [Cited by in Crossref: 127] [Cited by in F6Publishing: 110] [Article Influence: 18.1] [Reference Citation Analysis]
3 Tsutsumi LS, Owusu YB, Hurdle JG, Sun D. Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review. Curr Top Med Chem 2014;14:152-75. [PMID: 24236721 DOI: 10.2174/1568026613666131113154753] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
4 Coman V, Vodnar DC. Gut microbiota and old age: Modulating factors and interventions for healthy longevity. Exp Gerontol 2020;141:111095. [PMID: 32979504 DOI: 10.1016/j.exger.2020.111095] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
5 Chen Y, Gu H, Lv T, Yan D, Xu Q, Gu S, Shen P, Quan J, Fang Y, Chen L, Ye G, Li L. Longitudinal investigation of carriage rates and genotypes of toxigenic Clostridium difficile in hepatic cirrhosis patients. Epidemiol Infect 2019;147:e166. [PMID: 31063095 DOI: 10.1017/S0950268819000554] [Reference Citation Analysis]
6 Gaulke CA, Barton CL, Proffitt S, Tanguay RL, Sharpton TJ. Triclosan Exposure Is Associated with Rapid Restructuring of the Microbiome in Adult Zebrafish. PLoS One 2016;11:e0154632. [PMID: 27191725 DOI: 10.1371/journal.pone.0154632] [Cited by in Crossref: 79] [Cited by in F6Publishing: 74] [Article Influence: 13.2] [Reference Citation Analysis]
7 Rogers DS, Kundrapu S, Sunkesula VC, Donskey CJ. Comparison of perirectal versus rectal swabs for detection of asymptomatic carriers of toxigenic Clostridium difficile. J Clin Microbiol 2013;51:3421-2. [PMID: 23926162 DOI: 10.1128/JCM.01418-13] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
8 Thanissery R, Zeng D, Doyle RG, Theriot CM. A Small Molecule-Screening Pipeline to Evaluate the Therapeutic Potential of 2-Aminoimidazole Molecules Against Clostridium difficile. Front Microbiol 2018;9:1206. [PMID: 29928268 DOI: 10.3389/fmicb.2018.01206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
9 Ziakas PD, Zacharioudakis IM, Zervou FN, Grigoras C, Pliakos EE, Mylonakis E. Asymptomatic carriers of toxigenic C. difficile in long-term care facilities: a meta-analysis of prevalence and risk factors. PLoS One 2015;10:e0117195. [PMID: 25707002 DOI: 10.1371/journal.pone.0117195] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
10 Dharmarajan K, Strait KM, Lagu T, Lindenauer PK, Tinetti ME, Lynn J, Li SX, Krumholz HM. Acute decompensated heart failure is routinely treated as a cardiopulmonary syndrome. PLoS One 2013;8:e78222. [PMID: 24250751 DOI: 10.1371/journal.pone.0078222] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
11 Walk ST, Micic D, Galecki AT, Young VB, Aronoff DM. Understanding increased mortality in Clostridium difficile-infected older adults. Clin Infect Dis 2013;57:625-6. [PMID: 23658435 DOI: 10.1093/cid/cit310] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
12 Chiang SR, Lai CC, Ho CH, Chen CM, Chao CM, Wang JJ, Cheng KC. Prolonged Mechanical Ventilation Assistance Interacts Synergistically with Carbapenem for Clostridium difficile Infection in Critically Ill Patients. J Clin Med 2018;7:E224. [PMID: 30127264 DOI: 10.3390/jcm7080224] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
13 Cassir N, Fahsi N, Durand G, Lagier JC, Raoult D, Fournier PE. Emergence of Clostridium difficile tcdC variant 078 in Marseille, France. Eur J Clin Microbiol Infect Dis 2017;36:1971-4. [PMID: 28573471 DOI: 10.1007/s10096-017-3022-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
14 Eyre DW, Cule ML, Wilson DJ, Griffiths D, Vaughan A, O’Connor L, Ip CL, Golubchik T, Batty EM, Finney JM. Diverse sources of C. difficile infection identified on whole-genome sequencing. N Engl J Med. 2013;369:1195-1205. [PMID: 24066741 DOI: 10.1056/nejmoa1216064] [Cited by in Crossref: 442] [Cited by in F6Publishing: 243] [Article Influence: 49.1] [Reference Citation Analysis]
15 Hotinger JA, Morris ST, May AE. The Case against Antibiotics and for Anti-Virulence Therapeutics. Microorganisms 2021;9:2049. [PMID: 34683370 DOI: 10.3390/microorganisms9102049] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Azab M, Doo L, Doo DH, Elmofti Y, Ahmed M, Cadavona JJ, Liu XB, Shafi A, Joo MK, Yoo JW. Comparison of the Hospital-Acquired Clostridium difficile Infection Risk of Using Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists for Prophylaxis and Treatment of Stress Ulcers: A Systematic Review and Meta-Analysis. Gut Liver 2017;11:781-8. [PMID: 28506028 DOI: 10.5009/gnl16568] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
17 Trifan A, Stanciu C, Girleanu I, Stoica OC, Singeap AM, Maxim R, Chiriac SA, Ciobica A, Boiculese L. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis. World J Gastroenterol 2017; 23(35): 6500-6515 [PMID: 29085200 DOI: 10.3748/wjg.v23.i35.6500] [Cited by in CrossRef: 102] [Cited by in F6Publishing: 84] [Article Influence: 20.4] [Reference Citation Analysis]
18 Martin JSH, Monaghan TM, Wilcox MH. Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nat Rev Gastroenterol Hepatol 2016;13:206-16. [DOI: 10.1038/nrgastro.2016.25] [Cited by in Crossref: 166] [Cited by in F6Publishing: 144] [Article Influence: 27.7] [Reference Citation Analysis]
19 Shin JH, Chaves-Olarte E, Warren CA. Clostridium difficile Infection. Microbiol Spectr 2016;4. [PMID: 27337475 DOI: 10.1128/microbiolspec.EI10-0007-2015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
20 Dien Bard J, McElvania E. Panels and Syndromic Testing in Clinical Microbiology. Clin Lab Med 2020;40:393-420. [PMID: 33121611 DOI: 10.1016/j.cll.2020.08.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
21 Dubberke ER, Reske KA, Olsen MA, Bommarito K, Cleveland AA, Silveira FP, Schuster MG, Kauffman CA, Avery RK, Pappas PG, Chiller TM. Epidemiology and outcomes of Clostridium difficile infection in allogeneic hematopoietic cell and lung transplant recipients. Transpl Infect Dis 2018;20:e12855. [PMID: 29427356 DOI: 10.1111/tid.12855] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
22 Trifan A, Stanciu C, Stoica O, Girleanu I, Cojocariu C. Impact of Clostridium difficile infection on inflammatory bowel disease outcome: A review. World J Gastroenterol 2014; 20(33): 11736-11742 [PMID: 25206277 DOI: 10.3748/wjg.v20.i33.11736] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
23 Jordan S, Hui N, Doudle M, Von Papen M, Naik A, Lu CT, Nolan G, Cooper M. Incidence of Clostridioides difficile in patients post loop ileostomy reversal in an Australian tertiary hospital: a retrospective study. ANZ J Surg 2021. [PMID: 34889019 DOI: 10.1111/ans.17411] [Reference Citation Analysis]
24 Karyal C, Hughes J, Kelly ML, Luckett JC, Kaye PV, Cockayne A, Minton NP, Griffin R. Colonisation Factor CD0873, an Attractive Oral Vaccine Candidate against Clostridioides difficile. Microorganisms 2021;9:306. [PMID: 33540694 DOI: 10.3390/microorganisms9020306] [Reference Citation Analysis]
25 Bartsch SM, Curry SR, Harrison LH, Lee BY. The potential economic value of screening hospital admissions for Clostridium difficile. Eur J Clin Microbiol Infect Dis 2012;31:3163-71. [PMID: 22752150 DOI: 10.1007/s10096-012-1681-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
26 Barker AK, Scaria E, Safdar N, Alagoz O. Evaluation of the Cost-effectiveness of Infection Control Strategies to Reduce Hospital-Onset Clostridioides difficile Infection. JAMA Netw Open 2020;3:e2012522. [PMID: 32789514 DOI: 10.1001/jamanetworkopen.2020.12522] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
27 Gingras G, Guertin MH, Laprise JF, Drolet M, Brisson M. Mathematical Modeling of the Transmission Dynamics of Clostridium difficile Infection and Colonization in Healthcare Settings: A Systematic Review. PLoS One 2016;11:e0163880. [PMID: 27690247 DOI: 10.1371/journal.pone.0163880] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
28 Walsh TL, Bremmer DN, Moffa MA, Chan-Tompkins NH, Murillo MA, Chan L, Burkitt MJ, Konopka CI, Watson C, Trienski TL. Effect of Antimicrobial Stewardship Program Guidance on the Management of Uncomplicated Skin and Soft Tissue Infections in Hospitalized Adults. Mayo Clin Proc Innov Qual Outcomes 2017;1:91-9. [PMID: 30225405 DOI: 10.1016/j.mayocpiqo.2017.04.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Haran JP, Wu G, Bucci V, Fischer A, Boyer EW, Hibberd PL. Treatment of bacterial skin infections in ED observation units: factors influencing prescribing practice. Am J Emerg Med 2015;33:1780-5. [PMID: 26381681 DOI: 10.1016/j.ajem.2015.08.035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
30 Dingle KE, Didelot X, Quan TP, Eyre DW, Stoesser N, Golubchik T, Harding RM, Wilson DJ, Griffiths D, Vaughan A, Finney JM, Wyllie DH, Oakley SJ, Fawley WN, Freeman J, Morris K, Martin J, Howard P, Gorbach S, Goldstein EJC, Citron DM, Hopkins S, Hope R, Johnson AP, Wilcox MH, Peto TEA, Walker AS, Crook DW; Modernising Medical Microbiology Informatics Group. Effects of control interventions on Clostridium difficile infection in England: an observational study. Lancet Infect Dis 2017;17:411-21. [PMID: 28130063 DOI: 10.1016/S1473-3099(16)30514-X] [Cited by in Crossref: 196] [Cited by in F6Publishing: 80] [Article Influence: 39.2] [Reference Citation Analysis]
31 Kang JD, Myers CJ, Harris SC, Kakiyama G, Lee IK, Yun BS, Matsuzaki K, Furukawa M, Min HK, Bajaj JS, Zhou H, Hylemon PB. Bile Acid 7α-Dehydroxylating Gut Bacteria Secrete Antibiotics that Inhibit Clostridium difficile: Role of Secondary Bile Acids. Cell Chem Biol 2019;26:27-34.e4. [PMID: 30482679 DOI: 10.1016/j.chembiol.2018.10.003] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
32 Maharshak N, Barzilay I, Zinger H, Hod K, Dotan I. Clostridium difficile infection in hospitalized patients with inflammatory bowel disease: Prevalence, risk factors, and prognosis. Medicine (Baltimore) 2018;97:e9772. [PMID: 29384868 DOI: 10.1097/MD.0000000000009772] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 3.3] [Reference Citation Analysis]
33 Dong ZM, Chidi AP, Goswami J, Han K, Simmons RL, Rosengart MR, Tsung A. Prior inpatient admission increases the risk of post-operative infection in hepatobiliary and pancreatic surgery. HPB (Oxford) 2015;17:1105-12. [PMID: 26333471 DOI: 10.1111/hpb.12499] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
34 Hitschfeld M, Tovar E, Gupta S, Bik EM, Palmer C, Hoaglin MC, Almonacid DE, Richman J, Apte ZS. The role of a sequencing-based clinical intestinal screening test in patients at high-risk for Clostridium difficile and other pathogens: a case report. J Med Case Rep 2019;13:9. [PMID: 30642394 DOI: 10.1186/s13256-018-1919-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
35 Minalyan A, Gabrielyan L, Scott D, Jacobs J, Pisegna JR. The Gastric and Intestinal Microbiome: Role of Proton Pump Inhibitors. Curr Gastroenterol Rep. 2017;19:42. [PMID: 28733944 DOI: 10.1007/s11894-017-0577-6] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 8.8] [Reference Citation Analysis]
36 Raghunathan VM, Sheng I, Lim SH. Intestinal dysbiosis and allogeneic hematopoietic progenitor cell transplantation. J Transl Med 2016;14:335. [PMID: 27912759 DOI: 10.1186/s12967-016-1094-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
37 Daneman N, Guttmann A, Wang X, Ma X, Gibson D, Stukel TA. The association of hospital prevention processes and patient risk factors with the risk of Clostridium difficile infection: a population-based cohort study. BMJ Qual Saf 2015;24:435-43. [PMID: 25911052 DOI: 10.1136/bmjqs-2014-003863] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
38 Andersen KK, Strokappe NM, Hultberg A, Truusalu K, Smidt I, Mikelsaar RH, Mikelsaar M, Verrips T, Hammarström L, Marcotte H. Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies. Infect Immun 2016;84:395-406. [PMID: 26573738 DOI: 10.1128/IAI.00870-15] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
39 Blocker O, Abdulkadir U, Roberts P. Clostridium difficile-associated diarrhoea in primary joint arthroplasty in Aneurin Bevan University Health Board South. Ann R Coll Surg Engl 2016;98:222-5. [PMID: 26836055 DOI: 10.1308/rcsann.2016.0066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
40 Berkell M, Mysara M, Xavier BB, van Werkhoven CH, Monsieurs P, Lammens C, Ducher A, Vehreschild MJGT, Goossens H, de Gunzburg J, Bonten MJM, Malhotra-Kumar S; ANTICIPATE study group. Microbiota-based markers predictive of development of Clostridioides difficile infection. Nat Commun 2021;12:2241. [PMID: 33854066 DOI: 10.1038/s41467-021-22302-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Seekatz AM, Theriot CM, Rao K, Chang YM, Freeman AE, Kao JY, Young VB. Restoration of short chain fatty acid and bile acid metabolism following fecal microbiota transplantation in patients with recurrent Clostridium difficile infection. Anaerobe 2018;53:64-73. [PMID: 29654837 DOI: 10.1016/j.anaerobe.2018.04.001] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 17.8] [Reference Citation Analysis]
42 Eyre DW, Davies KA, Davis G, Fawley WN, Dingle KE, De Maio N, Karas A, Crook DW, Peto TEA, Walker AS, Wilcox MH; EUCLID Study Group. Two Distinct Patterns of Clostridium difficile Diversity Across Europe Indicating Contrasting Routes of Spread. Clin Infect Dis 2018;67:1035-44. [PMID: 29659747 DOI: 10.1093/cid/ciy252] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 12.0] [Reference Citation Analysis]
43 Baron SW, Ostrowsky BE, Nori P, Drory DY, Levi MH, Szymczak WA, Rinke ML, Southern WN. Screening of Clostridioides difficile carriers in an urban academic medical center: Understanding implications of disease. Infect Control Hosp Epidemiol 2020;41:149-53. [PMID: 31822302 DOI: 10.1017/ice.2019.309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
44 Lewis BB, Carter RA, Ling L, Leiner I, Taur Y, Kamboj M, Dubberke ER, Xavier J, Pamer EG. Pathogenicity Locus, Core Genome, and Accessory Gene Contributions to Clostridium difficile Virulence. mBio 2017;8:e00885-17. [PMID: 28790208 DOI: 10.1128/mBio.00885-17] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 5.6] [Reference Citation Analysis]
45 Sharaiha RZ, Freedberg DE, Abrams JA, Wang YC. Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett’s esophagus. Dig Dis Sci. 2014;59:1222-1230. [PMID: 24795040 DOI: 10.1007/s10620-014-3186-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
46 Fountain EM, Moses MC, Park LP, Woods CW, Arepally GM. Thrombocytopenia in hospitalized patients with severe clostridium difficile infection. J Thromb Thrombolysis 2017;43:38-42. [PMID: 27614757 DOI: 10.1007/s11239-016-1423-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
47 Ruff WE, Kriegel MA. Autoimmune host-microbiota interactions at barrier sites and beyond. Trends Mol Med 2015;21:233-44. [PMID: 25771098 DOI: 10.1016/j.molmed.2015.02.006] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 9.0] [Reference Citation Analysis]
48 Barletta JF, Sclar DA. Use of proton pump inhibitors for the provision of stress ulcer prophylaxis: clinical and economic consequences. Pharmacoeconomics 2014;32:5-13. [PMID: 24271943 DOI: 10.1007/s40273-013-0119-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Usacheva EA, Peterson LR, Mendoza K, Schora DM, Hossain MM, Jin JP. Cytoskeletal Tropomyosin as a Biomarker in Clostridium difficile Infection. J Clin Med Res 2019;11:98-105. [PMID: 30701001 DOI: 10.14740/jocmr3696] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
50 Keith JW, Dong Q, Sorbara MT, Becattini S, Sia JK, Gjonbalaj M, Seok R, Leiner IM, Littmann ER, Pamer EG. Impact of Antibiotic-Resistant Bacteria on Immune Activation and Clostridioides difficile Infection in the Mouse Intestine. Infect Immun 2020;88:e00362-19. [PMID: 31907198 DOI: 10.1128/IAI.00362-19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
51 Trifan A, Stoica O, Stanciu C, Cojocariu C, Singeap AM, Girleanu I, Miftode E. Clostridium difficile infection in patients with liver disease: a review. Eur J Clin Microbiol Infect Dis 2015;34:2313-24. [PMID: 26440041 DOI: 10.1007/s10096-015-2501-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
52 Tougas SR, Lodha N, Vandermeer B, Lorenzetti DL, Tarr PI, Tarr GAM, Chui L, Vanderkooi OG, Freedman SB. Prevalence of Detection of Clostridioides difficile Among Asymptomatic Children: A Systematic Review and Meta-analysis. JAMA Pediatr 2021;:e212328. [PMID: 34338715 DOI: 10.1001/jamapediatrics.2021.2328] [Reference Citation Analysis]
53 Sánchez-Pellicer P, Navarro-López V, González-Tamayo R, Llopis-Ruiz C, Núñez-Delegido E, Ruzafa-Costas B, Navarro-Moratalla L, Agüera-Santos J. Descriptive Study of Gut Microbiota in Infected and Colonized Subjects by Clostridiodes difficile. Microorganisms 2021;9:1727. [PMID: 34442805 DOI: 10.3390/microorganisms9081727] [Reference Citation Analysis]
54 Kuon C, Wannier R, Sterken D, Fang MC, Wolf J, Prasad PA. Are Antimotility Agents Safe for Use in Clostridioides difficile Infections? Results From an Observational Study in Malignant Hematology Patients. Mayo Clin Proc Innov Qual Outcomes 2020;4:792-800. [PMID: 33367215 DOI: 10.1016/j.mayocpiqo.2020.06.005] [Reference Citation Analysis]
55 Klöhn PC, Wuellner U, Zizlsperger N, Zhou Y, Tavares D, Berger S, Zettlitz KA, Proetzel G, Yong M, Begent RH, Reichert JM. IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA. MAbs 2013;5:178-201. [PMID: 23575266 DOI: 10.4161/mabs.23655] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
56 Furuya-Kanamori L, Marquess J, Yakob L, Riley TV, Paterson DL, Foster NF, Huber CA, Clements AC. Asymptomatic Clostridium difficile colonization: epidemiology and clinical implications. BMC Infect Dis 2015;15:516. [PMID: 26573915 DOI: 10.1186/s12879-015-1258-4] [Cited by in Crossref: 114] [Cited by in F6Publishing: 84] [Article Influence: 16.3] [Reference Citation Analysis]
57 Lamontagne F, Fowler RA, Adhikari NK, Murthy S, Brett-Major DM, Jacobs M, Uyeki TM, Vallenas C, Norris SL, Fischer WA 2nd, Fletcher TE, Levine AC, Reed P, Bausch DG, Gove S, Hall A, Shepherd S, Siemieniuk RA, Lamah MC, Kamara R, Nakyeyune P, Soka MJ, Edwin A, Hazzan AA, Jacob ST, Elkarsany MM, Adachi T, Benhadj L, Clément C, Crozier I, Garcia A, Hoffman SJ, Guyatt GH. Evidence-based guidelines for supportive care of patients with Ebola virus disease. Lancet 2018;391:700-8. [PMID: 29054555 DOI: 10.1016/S0140-6736(17)31795-6] [Cited by in Crossref: 55] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
58 Di Bella S, Paglia MG, Johnson E, Petrosillo N. Clostridium difficile 027 infection in Central Italy. BMC Infect Dis 2012;12:370. [PMID: 23259814 DOI: 10.1186/1471-2334-12-370] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
59 Hughes M, Qazi T, Berg A, Weinberg J, Chen X, Kelly CP, Farraye FA. Host Immune Response to Clostridium difficile Infection in Inflammatory Bowel Disease Patients. Inflamm Bowel Dis 2016;22:853-61. [PMID: 26954708 DOI: 10.1097/MIB.0000000000000696] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
60 Barkin JA, Nandi N, Miller N, Grace A, Barkin JS, Sussman DA. Superiority of the DNA amplification assay for the diagnosis of C. difficile infection: a clinical comparison of fecal tests. Dig Dis Sci. 2012;57:2592-2599. [PMID: 22576711 DOI: 10.1007/s10620-012-2200-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
61 Mohandas S, Soma VL, Tran TDB, Sodergren E, Ambooken T, Goldman DL, Weinstock G, Herold BC. Differences in Gut Microbiome in Hospitalized Immunocompetent vs. Immunocompromised Children, Including Those With Sickle Cell Disease. Front Pediatr 2020;8:583446. [PMID: 33282798 DOI: 10.3389/fped.2020.583446] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
62 Ilett EE, Helleberg M, Reekie J, Murray DD, Wulff SM, Khurana MP, Mocroft A, Daugaard G, Perch M, Rasmussen A, Sørensen SS, Gustafsson F, Frimodt-Møller N, Sengeløv H, Lundgren J. Incidence Rates and Risk Factors of Clostridioides difficile Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients. Open Forum Infect Dis 2019;6:ofz086. [PMID: 30949533 DOI: 10.1093/ofid/ofz086] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
63 Haran JP, Ward DV, Bhattarai SK, Loew E, Dutta P, Higgins A, McCormick BA, Bucci V. The high prevalence of Clostridioides difficile among nursing home elders associates with a dysbiotic microbiome. Gut Microbes 2021;13:1-15. [PMID: 33764826 DOI: 10.1080/19490976.2021.1897209] [Reference Citation Analysis]
64 Wijarnpreecha K, Aby ES, Kim D, Ungprasert P, Cheungpasitporn W, Thongprayoon C, Lukens FJ, Harnois DM, Kröner PT. The burden of Clostridioides difficile infection in patients with history of liver transplant and during index admission. Eur J Gastroenterol Hepatol 2021;33:894-8. [PMID: 32541243 DOI: 10.1097/MEG.0000000000001812] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Kumar A, Ghazanfar H, Davidson JM. A Rare Case of Arterial and Venous Thromboembolism in a Patient With Severe Clostridium difficile Infection. Cureus 2021;13:e16103. [PMID: 34258130 DOI: 10.7759/cureus.16103] [Reference Citation Analysis]
66 Drozd EM, Inocencio TJ, Braithwaite S, Jagun D, Shah H, Quon NC, Broderick KC, Kuti JL. Mortality, Hospital Costs, Payments, and Readmissions Associated With Clostridium difficile Infection Among Medicare Beneficiaries. Infect Dis Clin Pract (Baltim Md) 2015;23:318-23. [PMID: 27885315 DOI: 10.1097/IPC.0000000000000299] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
67 Kelly BJ, Tebas P. Clinical Practice and Infrastructure Review of Fecal Microbiota Transplantation for Clostridium difficile Infection. Chest. 2018;153:266-277. [PMID: 28923757 DOI: 10.1016/j.chest.2017.09.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
68 Lee P, Sinha AA, Soma VL, Cruz C, Wang T, Aroniadis O, Herold BC, Frenette PS, Goldman DL, Manwani D. Very low incidence of <i>Clostridioides difficile</i> infection in pediatric sickle cell disease patients. Haematologica 2020;106:1489-90. [PMID: 33054107 DOI: 10.3324/haematol.2019.244582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
69 Behar L, Chadwick D, Dunne A, Jones CI, Proctor C, Rajkumar C, Sharratt P, Stanley P, Whiley A, Wilks M, Llewelyn MJ. Toxigenic Clostridium difficile colonization among hospitalised adults; risk factors and impact on survival. J Infect 2017;75:20-5. [PMID: 28435086 DOI: 10.1016/j.jinf.2017.04.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
70 Mullish BH, Allegretti JR. The contribution of bile acid metabolism to the pathogenesis of Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:17562848211017725. [PMID: 34104212 DOI: 10.1177/17562848211017725] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Sartelli M, Di Bella S, McFarland LV, Khanna S, Furuya-Kanamori L, Abuzeid N, Abu-Zidan FM, Ansaloni L, Augustin G, Bala M, Ben-Ishay O, Biffl WL, Brecher SM, Camacho-Ortiz A, Caínzos MA, Chan S, Cherry-Bukowiec JR, Clanton J, Coccolini F, Cocuz ME, Coimbra R, Cortese F, Cui Y, Czepiel J, Demetrashvili Z, Di Carlo I, Di Saverio S, Dumitru IM, Eckmann C, Eiland EH, Forrester JD, Fraga GP, Frossard JL, Fry DE, Galeiras R, Ghnnam W, Gomes CA, Griffiths EA, Guirao X, Ahmed MH, Herzog T, Kim JI, Iqbal T, Isik A, Itani KMF, Labricciosa FM, Lee YY, Juang P, Karamarkovic A, Kim PK, Kluger Y, Leppaniemi A, Lohsiriwat V, Machain GM, Marwah S, Mazuski JE, Metan G, Moore EE, Moore FA, Ordoñez CA, Pagani L, Petrosillo N, Portela F, Rasa K, Rems M, Sakakushev BE, Segovia-Lohse H, Sganga G, Shelat VG, Spigaglia P, Tattevin P, Tranà C, Urbánek L, Ulrych J, Viale P, Baiocchi GL, Catena F. 2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. World J Emerg Surg 2019;14:8. [PMID: 30858872 DOI: 10.1186/s13017-019-0228-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 33] [Article Influence: 15.7] [Reference Citation Analysis]
72 Eyre DW, Griffiths D, Vaughan A, Golubchik T, Acharya M, O’Connor L, Crook DW, Walker AS, Peto TE. Asymptomatic Clostridium difficile colonisation and onward transmission. PLoS One. 2013;8:e78445. [PMID: 24265690 DOI: 10.1371/journal.pone.0078445] [Cited by in Crossref: 87] [Cited by in F6Publishing: 79] [Article Influence: 9.7] [Reference Citation Analysis]
73 Sheth PM, Douchant K, Uyanwune Y, Larocque M, Anantharajah A, Borgundvaag E, Dales L, McCreight L, McNaught L, Moore C, Ragan K, McGeer A, Broukhanski G. Evidence of transmission of Clostridium difficile in asymptomatic patients following admission screening in a tertiary care hospital. PLoS One 2019;14:e0207138. [PMID: 30742636 DOI: 10.1371/journal.pone.0207138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
74 McDonald LC, Diekema DJ. Point-Counterpoint: Active Surveillance for Carriers of Toxigenic Clostridium difficile Should Be Performed To Guide Prevention Efforts. J Clin Microbiol 2018;56:e00782-18. [PMID: 29769275 DOI: 10.1128/JCM.00782-18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
75 Giacobbe DR, Dettori S, Di Bella S, Vena A, Granata G, Luzzati R, Petrosillo N, Bassetti M. Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies. Infect Dis Ther 2020;9:481-94. [PMID: 32632582 DOI: 10.1007/s40121-020-00314-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
76 Azimirad M, Krutova M, Yadegar A, Shahrokh S, Olfatifar M, Aghdaei HA, Fawley WN, Wilcox MH, Zali MR. Clostridioides difficile ribotypes 001 and 126 were predominant in Tehran healthcare settings from 2004 to 2018: a 14-year-long cross-sectional study. Emerg Microbes Infect 2020;9:1432-43. [PMID: 32520657 DOI: 10.1080/22221751.2020.1780949] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
77 Salmasian H, Freedberg DE, Abrams JA, Friedman C. An automated tool for detecting medication overuse based on the electronic health records. Pharmacoepidemiol Drug Saf 2013;22:183-9. [PMID: 23233423 DOI: 10.1002/pds.3387] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
78 Chamchod F, Palittapongarnpim P. Modeling Clostridium difficile in a hospital setting: control and admissions of colonized and symptomatic patients. Theor Biol Med Model 2019;16:2. [PMID: 30704484 DOI: 10.1186/s12976-019-0098-0] [Reference Citation Analysis]
79 Gibson MK, Pesesky MW, Dantas G. The yin and yang of bacterial resilience in the human gut microbiota. J Mol Biol 2014;426:3866-76. [PMID: 24911583 DOI: 10.1016/j.jmb.2014.05.029] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 5.8] [Reference Citation Analysis]
80 Czepiel J, Krutova M, Mizrahi A, Khanafer N, Enoch DA, Patyi M, Deptuła A, Agodi A, Nuvials X, Pituch H, Wójcik-Bugajska M, Filipczak-Bryniarska I, Brzozowski B, Krzanowski M, Konturek K, Fedewicz M, Michalak M, Monpierre L, Vanhems P, Gouliouris T, Jurczyszyn A, Goldman-Mazur S, Wultańska D, Kuijper EJ, Skupień J, Biesiada G, Garlicki A. Mortality Following Clostridioides difficile Infection in Europe: A Retrospective Multicenter Case-Control Study. Antibiotics (Basel) 2021;10:299. [PMID: 33805755 DOI: 10.3390/antibiotics10030299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
81 Curry S. Clostridium difficile. Clin Lab Med. 2010;30:329-342. [PMID: 20513554 DOI: 10.1016/j.cll.2010.04.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
82 Guh AY, McDonald LC. Active Surveillance and Isolation of Asymptomatic Carriers of Clostridium difficile at Hospital Admission: Containing What Lies Under the Waterline. JAMA Intern Med 2016;176:805-6. [PMID: 27111468 DOI: 10.1001/jamainternmed.2016.1118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
83 Henriksson G, Bredberg J, Wullt M, Lyrenäs E, Hindorf U, Ohlsson B, Grip O. Humoral response to Clostridium difficile in inflammatory bowel disease, including correlation with immunomodulatory treatment. JGH Open 2019;3:154-8. [PMID: 31061891 DOI: 10.1002/jgh3.12122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
84 Pilate T, Verhaegen J, Van Ranst M, Saegeman V. Binary toxin and its clinical importance in Clostridium difficile infection, Belgium. Eur J Clin Microbiol Infect Dis 2016;35:1741-7. [PMID: 27393490 DOI: 10.1007/s10096-016-2719-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
85 Dubberke ER, Reske KA, Seiler S, Hink T, Kwon JH, Burnham CA. Risk Factors for Acquisition and Loss of Clostridium difficile Colonization in Hospitalized Patients. Antimicrob Agents Chemother 2015;59:4533-43. [PMID: 25987626 DOI: 10.1128/AAC.00642-15] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
86 Kriss M, Hazleton KZ, Nusbacher NM, Martin CG, Lozupone CA. Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery. Curr Opin Microbiol. 2018;44:34-40. [PMID: 30036705 DOI: 10.1016/j.mib.2018.07.003] [Cited by in Crossref: 105] [Cited by in F6Publishing: 96] [Article Influence: 26.3] [Reference Citation Analysis]
87 Khanafer N, Vanhems P, Bennia S, Martin-Gaujard G, Juillard L, Rimmelé T, Argaud L, Martin O, Huriaux L, Marcotte G, Hernu R, Floccard B, Cassier P, Group S. Factors Associated with Clostridioides (Clostridium) Difficile Infection and Colonization: Ongoing Prospective Cohort Study in a French University Hospital. Int J Environ Res Public Health 2021;18:7528. [PMID: 34299978 DOI: 10.3390/ijerph18147528] [Reference Citation Analysis]
88 Eyre DW, Laager M, Walker AS, Cooper BS, Wilson DJ; CDC Modeling Infectious Diseases in Healthcare Program (MInD-Healthcare). Probabilistic transmission models incorporating sequencing data for healthcare-associated Clostridioides difficile outperform heuristic rules and identify strain-specific differences in transmission. PLoS Comput Biol 2021;17:e1008417. [PMID: 33444378 DOI: 10.1371/journal.pcbi.1008417] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Terveer EM, Crobach MJ, Sanders IM, Vos MC, Verduin CM, Kuijper EJ. Detection of Clostridium difficile in Feces of Asymptomatic Patients Admitted to the Hospital. J Clin Microbiol 2017;55:403-11. [PMID: 27852676 DOI: 10.1128/JCM.01858-16] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
90 Furuya-Kanamori L, Riley TV, Paterson DL, Foster NF, Huber CA, Hong S, Harris-Brown T, Robson J, Clements AC. Comparison of Clostridium difficile Ribotypes Circulating in Australian Hospitals and Communities. J Clin Microbiol 2017;55:216-25. [PMID: 27807147 DOI: 10.1128/JCM.01779-16] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
91 Lan N, Ashburn J, Shen B. Fecal microbiota transplantation for Clostridium difficile infection in patients with ileal pouches. Gastroenterol Rep (Oxf). 2017;5:200-207. [PMID: 28852524 DOI: 10.1093/gastro/gox018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
92 Hudson LE, Anderson SE, Corbett AH, Lamb TJ. Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. Clin Microbiol Rev. 2017;30:191-231. [PMID: 27856521 DOI: 10.1128/cmr.00049-16] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 7.6] [Reference Citation Analysis]
93 Kim HS, Kang JH, Kim HG, Kim YH, Bae H, Kim NK. Clostridium difficile Infection After Ileostomy Reversal. Ann Coloproctol 2021;37:S4-6. [PMID: 32178491 DOI: 10.3393/ac.2019.09.24] [Reference Citation Analysis]
94 Jose S, Madan R. Neutrophil-mediated inflammation in the pathogenesis of Clostridium difficile infections. Anaerobe 2016;41:85-90. [PMID: 27063896 DOI: 10.1016/j.anaerobe.2016.04.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
95 Origüen J, Fernández-Ruiz M, Lumbreras C, Orellana MÁ, López-Medrano F, Ruiz-Merlo T, San Juan R, García-Reyne A, González E, Polanco N, Paz-Artal E, Andrés A, Aguado JM. Potential role of post-transplant hypogammaglobulinemia in the risk of Clostridium difficile infection after kidney transplantation: a case-control study. Infection 2015;43:413-22. [PMID: 25676130 DOI: 10.1007/s15010-015-0737-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
96 Borren NZ, Ghadermarzi S, Hutfless S, Ananthakrishnan AN. The emergence of Clostridium difficile infection in Asia: A systematic review and meta-analysis of incidence and impact. PLoS One 2017;12:e0176797. [PMID: 28463987 DOI: 10.1371/journal.pone.0176797] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 8.8] [Reference Citation Analysis]
97 Nakao S, Hasegawa S, Shimada K, Mukai R, Tanaka M, Matsumoto K, Uranishi H, Masuta M, Ikesue H, Hashida T, Iguchi K, Nakamura M. Evaluation of anti-infective-related Clostridium difficile-associated colitis using the Japanese Adverse Drug Event Report database. Int J Med Sci 2020;17:921-30. [PMID: 32308545 DOI: 10.7150/ijms.43789] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
98 Haran JP, Hayward G, Skinner S, Merritt C, Hoaglin DC, Hibberd PL, Lu S, Boyer EW. Factors influencing the development of antibiotic associated diarrhea in ED patients discharged home: risk of administering IV antibiotics. Am J Emerg Med 2014;32:1195-9. [PMID: 25149599 DOI: 10.1016/j.ajem.2014.07.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
99 Wongkuna S, Janvilisri T, Phanchana M, Harnvoravongchai P, Aroonnual A, Aimjongjun S, Malaisri N, Chankhamhaengdecha S. Temporal Variations in Patterns of Clostridioides difficile Strain Diversity and Antibiotic Resistance in Thailand. Antibiotics (Basel) 2021;10:714. [PMID: 34199301 DOI: 10.3390/antibiotics10060714] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
100 Allen VA, Manahan KJ, Geisler JP. Recurrent Pseudomembranous Colitis in an Ovarian Cancer Patient Undergoing Carboplatin Chemotherapy. Case Rep Obstet Gynecol 2016;2016:7540302. [PMID: 27051544 DOI: 10.1155/2016/7540302] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
101 Joshi NM, Rampton DS. Commentary: predictors of severe outcomes associated with Clostridium difficile infection in inflammatory bowel disease patients. Aliment Pharmacol Ther 2012;35:1108. [PMID: 25123206 DOI: 10.1111/j.1365-2036.2012.05071.x] [Reference Citation Analysis]
102 Rolston KV. Infections in Cancer Patients with Solid Tumors: A Review. Infect Dis Ther. 2017;6:69-83. [PMID: 28160269 DOI: 10.1007/s40121-017-0146-1] [Cited by in Crossref: 89] [Cited by in F6Publishing: 77] [Article Influence: 17.8] [Reference Citation Analysis]
103 Collier A, McLaren J, Godwin J, Bal A. Is Clostridium difficile associated with the '4C' antibiotics? A retrospective observational study in diabetic foot ulcer patients. Int J Clin Pract 2014;68:628-32. [PMID: 24499256 DOI: 10.1111/ijcp.12347] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
104 Vogelzang EH, Lankelma JM, van Mansfeld R, van Prehn J, van Houdt R. Implementing a Clostridium difficile testing algorithm and its effect on isolation duration and treatment initiation: a pre- and post-implementation study. Eur J Clin Microbiol Infect Dis 2020;39:1071-6. [PMID: 31970532 DOI: 10.1007/s10096-020-03823-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
105 O'Hagan JJ, McDonald LC. The Challenges of Tracking Clostridium difficile to Its Source in Hospitalized Patients. Clin Infect Dis 2019;68:210-2. [PMID: 29846537 DOI: 10.1093/cid/ciy461] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
106 Zhou FF, Wu S, Klena JD, Huang HH. Clinical characteristics of Clostridium difficile infection in hospitalized patients with antibiotic-associated diarrhea in a university hospital in China. Eur J Clin Microbiol Infect Dis 2014;33:1773-9. [PMID: 24820293 DOI: 10.1007/s10096-014-2132-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
107 Garey KW. Perils, Pitfalls, and Promise of Primary Prophylaxis for Clostridioides difficile Infection. Clin Infect Dis 2020;71:1140-1. [PMID: 31560048 DOI: 10.1093/cid/ciz970] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
108 Song M, Dilworth TJ, Munson E, Davis J, Elshaboury RH. Results of a local combination therapy antibiogram for Pseudomonas aeruginosa isolates: is double worth the trouble? Ther Adv Infect Dis 2017;4:165-70. [PMID: 29662672 DOI: 10.1177/2049936117725935] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
109 Kampouri E, Croxatto A, Prod'hom G, Guery B. Clostridioides difficile Infection, Still a Long Way to Go. J Clin Med 2021;10:389. [PMID: 33498428 DOI: 10.3390/jcm10030389] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
110 Knetsch CW, Connor TR, Mutreja A, van Dorp SM, Sanders IM, Browne HP, Harris D, Lipman L, Keessen EC, Corver J, Kuijper EJ, Lawley TD. Whole genome sequencing reveals potential spread of Clostridium difficile between humans and farm animals in the Netherlands, 2002 to 2011. Euro Surveill 2014;19:20954. [PMID: 25411691 DOI: 10.2807/1560-7917.es2014.19.45.20954] [Cited by in Crossref: 134] [Cited by in F6Publishing: 60] [Article Influence: 16.8] [Reference Citation Analysis]
111 Akamine CM, Ing MB, Jackson CS, Loo LK. The efficacy of intracolonic vancomycin for severe Clostridium difficile colitis: a case series. BMC Infect Dis 2016;16:316. [PMID: 27388627 DOI: 10.1186/s12879-016-1657-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
112 Schwartz KL, Darwish I, Richardson SE, Mulvey MR, Thampi N. Severe clinical outcome is uncommon in Clostridium difficile infection in children: a retrospective cohort study. BMC Pediatr. 2014;14:28. [PMID: 24485120 DOI: 10.1186/1471-2431-14-28] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
113 Cugini C, Ramasubbu N, Tsiagbe VK, Fine DH. Dysbiosis From a Microbial and Host Perspective Relative to Oral Health and Disease. Front Microbiol 2021;12:617485. [PMID: 33763040 DOI: 10.3389/fmicb.2021.617485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
114 Stiles BG, Pradhan K, Fleming JM, Samy RP, Barth H, Popoff MR. Clostridium and bacillus binary enterotoxins: bad for the bowels, and eukaryotic being. Toxins (Basel) 2014;6:2626-56. [PMID: 25198129 DOI: 10.3390/toxins6092626] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 5.5] [Reference Citation Analysis]
115 Dumic I, Nordin T, Jecmenica M, Stojkovic Lalosevic M, Milosavljevic T, Milovanovic T. Gastrointestinal Tract Disorders in Older Age. Can J Gastroenterol Hepatol 2019;2019:6757524. [PMID: 30792972 DOI: 10.1155/2019/6757524] [Cited by in Crossref: 51] [Cited by in F6Publishing: 28] [Article Influence: 17.0] [Reference Citation Analysis]
116 Czepiel J, Dróżdż M, Pituch H, Kuijper EJ, Perucki W, Mielimonka A, Goldman S, Wultańska D, Garlicki A, Biesiada G. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis 2019;38:1211-21. [PMID: 30945014 DOI: 10.1007/s10096-019-03539-6] [Cited by in Crossref: 87] [Cited by in F6Publishing: 75] [Article Influence: 29.0] [Reference Citation Analysis]
117 Faleck DM, Salmasian H, Furuya EY, Larson EL, Abrams JA, Freedberg DE. Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit. Am J Gastroenterol. 2016;111:1641-1648. [PMID: 27575714 DOI: 10.1038/ajg.2016.343] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 7.7] [Reference Citation Analysis]
118 Lau CS, Chamberlain RS. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med. 2016;9:27-37. [PMID: 26955289 DOI: 10.2147/ijgm.s98280] [Cited by in Crossref: 28] [Cited by in F6Publishing: 45] [Article Influence: 4.7] [Reference Citation Analysis]
119 Almeida J, Silva R, Lobato F, Mota R. Isolation of Clostridium perfringens and C. difficile in crab-eating fox ( Cerdocyon thous - Linnaeus 1776) from Northeastern Brazil. Arq Bras Med Vet Zootec 2018;70:1709-13. [DOI: 10.1590/1678-4162-9895] [Reference Citation Analysis]
120 Muñoz-Price LS, Hanson R, Singh S, Nattinger AB, Penlesky A, Buchan BW, Ledeboer NA, Beyer K, Namin S, Zhou Y, Pezzin LE. Association Between Environmental Factors and Toxigenic Clostridioides difficile Carriage at Hospital Admission. JAMA Netw Open 2020;3:e1919132. [PMID: 31922563 DOI: 10.1001/jamanetworkopen.2019.19132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
121 Peterfreund GL, Vandivier LE, Sinha R, Marozsan AJ, Olson WC, Zhu J, Bushman FD. Succession in the gut microbiome following antibiotic and antibody therapies for Clostridium difficile. PLoS One 2012;7:e46966. [PMID: 23071679 DOI: 10.1371/journal.pone.0046966] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 6.4] [Reference Citation Analysis]
122 Nitzan O, Elias M, Chazan B, Raz R, Saliba W. Clostridium difficile and inflammatory bowel disease: Role in pathogenesis and implications in treatment. World J Gastroenterol 2013; 19(43): 7577-7585 [PMID: 24282348 DOI: 10.3748/wjg.v19.i43.7577] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 48] [Article Influence: 7.0] [Reference Citation Analysis]
123 Harbarth S, Samore MH. Clostridium: transmission difficile? PLoS Med 2012;9:e1001171. [PMID: 22346737 DOI: 10.1371/journal.pmed.1001171] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
124 Scaria J, Mao C, Chen JW, McDonough SP, Sobral B, Chang YF. Differential stress transcriptome landscape of historic and recently emerged hypervirulent strains of Clostridium difficile strains determined using RNA-seq. PLoS One 2013;8:e78489. [PMID: 24244315 DOI: 10.1371/journal.pone.0078489] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
125 Wang B, Lv Z, Zhang P, Su J. Molecular epidemiology and antimicrobial susceptibility of human Clostridium difficile isolates from a single institution in Northern China. Medicine (Baltimore) 2018;97:e11219. [PMID: 29924052 DOI: 10.1097/MD.0000000000011219] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
126 Heidebrecht HJ, Lagkouvardos I, Reitmeier S, Hengst C, Kulozik U, Pfaffl MW. Alteration of Intestinal Microbiome of Clostridioides difficile-Infected Hamsters during the Treatment with Specific Cow Antibodies. Antibiotics (Basel) 2021;10:724. [PMID: 34208527 DOI: 10.3390/antibiotics10060724] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
127 Bhargava A, Clifton MS, Mhaske P, Liao M, Pothoulakis C, Leeman SE, Grady EF. Local injection of dsRNA targeting calcitonin receptor-like receptor (CLR) ameliorates Clostridium difficile toxin A-induced ileitis. Proc Natl Acad Sci U S A 2013;110:731-6. [PMID: 23267070 DOI: 10.1073/pnas.1219733110] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
128 Baker SJ, Chu DI. Physical, Laboratory, Radiographic, and Endoscopic Workup for Clostridium difficile Colitis. Clin Colon Rectal Surg 2020;33:82-6. [PMID: 32104160 DOI: 10.1055/s-0039-3400474] [Reference Citation Analysis]
129 Zhao X, Bender F, Shukla R, Kang JJ, Caro-Aguilar I, Laterza OF. Sensitive assays enable detection of serum IgG antibodies against Clostridium difficile toxin A and toxin B in healthy subjects and patients with Clostridium difficile infection. Bioanalysis 2016;8:611-23. [PMID: 26964649 DOI: 10.4155/bio-2015-0033] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
130 Alonso CD, Dufresne SF, Hanna DB, Labbé AC, Treadway SB, Neofytos D, Bélanger S, Huff CA, Laverdière M, Marr KA. Clostridium difficile infection after adult autologous stem cell transplantation: a multicenter study of epidemiology and risk factors. Biol Blood Marrow Transplant 2013;19:1502-8. [PMID: 23916741 DOI: 10.1016/j.bbmt.2013.07.022] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
131 Kim SH, Lim KR, Lee H, Huh K, Cho SY, Kang CI, Chung DR, Peck KR. Clinical effectiveness of oral antimicrobial therapy for acute pyelonephritis caused by extended-spectrum β-lactamase-producing Enterobacteriales. Eur J Clin Microbiol Infect Dis 2020;39:159-67. [PMID: 31520270 DOI: 10.1007/s10096-019-03705-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
132 Monaghan TM, Robins A, Knox A, Sewell HF, Mahida YR. Circulating antibody and memory B-Cell responses to C. difficile toxins A and B in patients with C. difficile-associated diarrhoea, inflammatory bowel disease and cystic fibrosis. PLoS One. 2013;8:e74452. [PMID: 24058568 DOI: 10.1371/journal.pone.0074452] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
133 Keessen EC, Harmanus C, Dohmen W, Kuijper EJ, Lipman LJ. Clostridium difficile infection associated with pig farms. Emerg Infect Dis 2013;19:1032-4. [PMID: 23735347 DOI: 10.3201/eid1906.121645] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
134 Grigoras CA, Zervou FN, Zacharioudakis IM, Siettos CI, Mylonakis E. Isolation of C. difficile Carriers Alone and as Part of a Bundle Approach for the Prevention of Clostridium difficile Infection (CDI): A Mathematical Model Based on Clinical Study Data. PLoS One 2016;11:e0156577. [PMID: 27258068 DOI: 10.1371/journal.pone.0156577] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
135 Ahmad O, Crawford TN, Arora V, Maskey MK. Laboratory markers predictive of fulminant Clostridioides difficile infection refractory to fluid resuscitation. Infect Prev Pract 2021;3:100127. [PMID: 34368744 DOI: 10.1016/j.infpip.2021.100127] [Reference Citation Analysis]
136 Haider A, Alavi F, Siddiqa A, Abbas H, Patel H. Fulminant Pseudomembranous Colitis Leading to Clostridium Paraputrificum Bacteremia. Cureus 2021;13:e13763. [PMID: 33842139 DOI: 10.7759/cureus.13763] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Azimirad M, Noori M, Raeisi H, Yadegar A, Shahrokh S, Asadzadeh Aghdaei H, Bentivegna E, Martelletti P, Petrosillo N, Zali MR. How Does COVID-19 Pandemic Impact on Incidence of Clostridioides difficile Infection and Exacerbation of Its Gastrointestinal Symptoms? Front Med (Lausanne) 2021;8:775063. [PMID: 34966759 DOI: 10.3389/fmed.2021.775063] [Reference Citation Analysis]
138 Gerding DN, Kelly CP, Rahav G, Lee C, Dubberke ER, Kumar PN, Yacyshyn B, Kao D, Eves K, Ellison MC, Hanson ME, Guris D, Dorr MB. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence. Clin Infect Dis 2018;67:649-56. [PMID: 29538686 DOI: 10.1093/cid/ciy171] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 24.0] [Reference Citation Analysis]
139 Kazanowski M, Smolarek S, Kinnarney F, Grzebieniak Z. Clostridium difficile: epidemiology, diagnostic and therapeutic possibilities-a systematic review. Tech Coloproctol. 2014;18:223-232. [PMID: 24178946 DOI: 10.1007/s10151-013-1081-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
140 Cheng YW, Fischer M. The Present Status of Fecal Microbiota Transplantation and Its Value in the Elderly. Curr Treat Options Gastroenterol 2017;15:349-62. [PMID: 28748314 DOI: 10.1007/s11938-017-0143-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
141 Freedberg DE, Lamousé-Smith ES, Lightdale JR, Jin Z, Yang YX, Abrams JA. Use of Acid Suppression Medication is Associated With Risk for C. difficile Infection in Infants and Children: A Population-based Study. Clin Infect Dis 2015;61:912-7. [PMID: 26060292 DOI: 10.1093/cid/civ432] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 6.4] [Reference Citation Analysis]
142 Pacyga K, Razim A, Martirosian G, Aptekorz M, Szuba A, Gamian A, Myc A, Górska S. The Bioinformatic and In Vitro Studies of Clostridioides Difficile Aminopeptidase M24 Revealed the Immunoreactive KKGIK Peptide. Cells 2020;9:E1146. [PMID: 32392707 DOI: 10.3390/cells9051146] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
143 Asgary R, Snead JA, Wahid NA, Ro V, Halim M, Stribling JC. Risks and Preventive Strategies for Clostridioides difficile Transmission to Household or Community Contacts during Transition in Healthcare Settings. Emerg Infect Dis 2021;27:1776-82. [PMID: 34152967 DOI: 10.3201/eid2707.200209] [Reference Citation Analysis]
144 Cho J, Cunningham S, Pu M, Lennon RJ, Dens Higano J, Jeraldo P, Sampathkumar P, Shannon S, Kashyap PC, Patel R. Clostridioides difficile Whole-genome Sequencing Differentiates Relapse With the Same Strain From Reinfection With a New Strain. Clin Infect Dis 2021;72:806-13. [PMID: 32064535 DOI: 10.1093/cid/ciaa159] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
145 Durham DP, Olsen MA, Dubberke ER, Galvani AP, Townsend JP. Quantifying Transmission of Clostridium difficile within and outside Healthcare Settings. Emerg Infect Dis 2016;22:608-16. [PMID: 26982504 DOI: 10.3201/eid2204.150455] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
146 Velez DR, Ahmeti M. Clostridioides difficile Enteritis Induced Anastomotic Rupture: A Case Report and Literature Review. Case Rep Surg 2020;2020:9794823. [PMID: 32607274 DOI: 10.1155/2020/9794823] [Reference Citation Analysis]
147 Madan R, Petri WA Jr. Immune responses to Clostridium difficile infection. Trends Mol Med 2012;18:658-66. [PMID: 23084763 DOI: 10.1016/j.molmed.2012.09.005] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 6.5] [Reference Citation Analysis]
148 Hung YP, Tsai PJ, Hung KH, Liu HC, Lee CI, Lin HJ, Wu YH, Wu JJ, Ko WC. Impact of toxigenic Clostridium difficile colonization and infection among hospitalized adults at a district hospital in southern Taiwan. PLoS One 2012;7:e42415. [PMID: 22876321 DOI: 10.1371/journal.pone.0042415] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
149 Wang H, Sun X, Zhang Y, Li S, Chen K, Shi L, Nie W, Kumar R, Tzipori S, Wang J. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun. 2012;80:2678-2688. [PMID: 22615245 DOI: 10.1128/iai.00215-12] [Cited by in Crossref: 60] [Cited by in F6Publishing: 46] [Article Influence: 6.0] [Reference Citation Analysis]
150 Jung HK, Tae CH, Song KH, Kang SJ, Park JK, Gong EJ, Shin JE, Lim HC, Lee SK, Jung DH, Choi YJ, Seo SI, Kim JS, Lee JM, Kim BJ, Kang SH, Park CH, Choi SC, Kwon JG, Park KS, Park MI, Lee TH, Kim SY, Cho YS, Lee HH, Jung KW, Kim DH, Moon HS, Miwa H, Chen CL, Gonlachanvit S, Ghoshal UC, Wu JCY, Siah KTH, Hou X, Oshima T, Choi MY, Lee KJ; Korean Society of Neurogastroenterology and Motility. 2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease. J Neurogastroenterol Motil 2021;27:453-81. [PMID: 34642267 DOI: 10.5056/jnm21077] [Reference Citation Analysis]
151 Latorre M, Krishnareddy S, Freedberg DE. Microbiome as mediator: Do systemic infections start in the gut? World J Gastroenterol 2015; 21(37): 10487-10492 [PMID: 26457009 DOI: 10.3748/wjg.v21.i37.10487] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
152 Sartelli M, Malangoni MA, Abu-Zidan FM, Griffiths EA, Di Bella S, McFarland LV, Eltringham I, Shelat VG, Velmahos GC, Kelly CP, Khanna S, Abdelsattar ZM, Alrahmani L, Ansaloni L, Augustin G, Bala M, Barbut F, Ben-Ishay O, Bhangu A, Biffl WL, Brecher SM, Camacho-Ortiz A, Caínzos MA, Canterbury LA, Catena F, Chan S, Cherry-Bukowiec JR, Clanton J, Coccolini F, Cocuz ME, Coimbra R, Cook CH, Cui Y, Czepiel J, Das K, Demetrashvili Z, Di Carlo I, Di Saverio S, Dumitru IM, Eckert C, Eckmann C, Eiland EH, Enani MA, Faro M, Ferrada P, Forrester JD, Fraga GP, Frossard JL, Galeiras R, Ghnnam W, Gomes CA, Gorrepati V, Ahmed MH, Herzog T, Humphrey F, Kim JI, Isik A, Ivatury R, Lee YY, Juang P, Furuya-Kanamori L, Karamarkovic A, Kim PK, Kluger Y, Ko WC, LaBarbera FD, Lee JG, Leppaniemi A, Lohsiriwat V, Marwah S, Mazuski JE, Metan G, Moore EE, Moore FA, Nord CE, Ordoñez CA, Júnior GA, Petrosillo N, Portela F, Puri BK, Ray A, Raza M, Rems M, Sakakushev BE, Sganga G, Spigaglia P, Stewart DB, Tattevin P, Timsit JF, To KB, Tranà C, Uhl W, Urbánek L, van Goor H, Vassallo A, Zahar JR, Caproli E, Viale P. WSES guidelines for management of Clostridium difficile infection in surgical patients. World J Emerg Surg 2015;10:38. [PMID: 26300956 DOI: 10.1186/s13017-015-0033-6] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 7.7] [Reference Citation Analysis]
153 Dos Santos-Schaller O, Boisset S, Seigneurin A, Epaulard O. Recurrence and death after Clostridium difficile infection: gender-dependant influence of proton pump inhibitor therapy. Springerplus 2016;5:430. [PMID: 27104118 DOI: 10.1186/s40064-016-2058-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
154 El Feghaly RE, Stauber JL, Deych E, Gonzalez C, Tarr PI, Haslam DB. Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. Clin Infect Dis. 2013;56:1713-1721. [PMID: 23487367 DOI: 10.1093/cid/cit147] [Cited by in Crossref: 102] [Cited by in F6Publishing: 99] [Article Influence: 11.3] [Reference Citation Analysis]
155 Hunter JC, Mu Y, Dumyati GK, Farley MM, Winston LG, Johnston HL, Meek JI, Perlmutter R, Holzbauer SM, Beldavs ZG, Phipps EC, Dunn JR, Cohen JA, Avillan J, Stone ND, Gerding DN, McDonald LC, Lessa FC. Burden of Nursing Home-Onset Clostridium difficile Infection in the United States: Estimates of Incidence and Patient Outcomes. Open Forum Infect Dis 2016;3:ofv196. [PMID: 26798767 DOI: 10.1093/ofid/ofv196] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
156 Oezguen N, Power TD, Urvil P, Feng H, Pothoulakis C, Stamler JS, Braun W, Savidge TC. Clostridial toxins: sensing a target in a hostile gut environment. Gut Microbes 2012;3:35-41. [PMID: 22356854 DOI: 10.4161/gmic.19250] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
157 Alonso CD, Marr KA. Clostridium difficile infection among hematopoietic stem cell transplant recipients: beyond colitis. Curr Opin Infect Dis 2013;26:326-31. [PMID: 23806895 DOI: 10.1097/QCO.0b013e3283630c4c] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 3.1] [Reference Citation Analysis]
158 Madan R, Petri WA Jr. Role of obesity and adipose tissue-derived cytokine leptin during Clostridium difficile infection. Anaerobe 2015;34:182-6. [PMID: 25638400 DOI: 10.1016/j.anaerobe.2014.12.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
159 Barker AK, Alagoz O, Safdar N. Interventions to Reduce the Incidence of Hospital-Onset Clostridium difficile Infection: An Agent-Based Modeling Approach to Evaluate Clinical Effectiveness in Adult Acute Care Hospitals. Clin Infect Dis 2018;66:1192-203. [PMID: 29112710 DOI: 10.1093/cid/cix962] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
160 Michal Stevens A, Esposito DH, Stoney RJ, Hamer DH, Flores-Figueroa J, Bottieau E, Connor BA, Gkrania-Klotsas E, Goorhuis A, Hynes NA, Libman M, Lopez-Velez R, McCarthy AE, von Sonnenburg F, Schwartz E, van Genderen PJ, Scott Benson L, Leung DT; GeoSentinel Surveillance Network. Clostridium difficile infection in returning travellers. J Travel Med 2017;24. [PMID: 28355613 DOI: 10.1093/jtm/taw099] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
161 Jump RL, Donskey CJ. Clostridium difficile in the Long-Term Care Facility: Prevention and Management. Curr Geriatr Rep 2015;4:60-9. [PMID: 25685657 DOI: 10.1007/s13670-014-0108-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
162 Rodríguez Garzotto A, Mérida García A, Muñoz Unceta N, Galera Lopez MM, Orellana-miguel MÁ, Díaz-garcía CV, Cortijo-cascajares S, Cortes-funes H, Agulló-ortuño MT. Risk factors associated with Clostridium difficile infection in adult oncology patients. Support Care Cancer 2015;23:1569-77. [DOI: 10.1007/s00520-014-2506-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
163 Sun X, Hirota SA. The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection. Mol Immunol. 2015;63:193-202. [PMID: 25242213 DOI: 10.1016/j.molimm.2014.09.005] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
164 Asempa TE, Nicolau DP. Clostridium difficile infection in the elderly: an update on management. Clin Interv Aging 2017;12:1799-809. [PMID: 29123385 DOI: 10.2147/CIA.S149089] [Cited by in Crossref: 38] [Cited by in F6Publishing: 18] [Article Influence: 7.6] [Reference Citation Analysis]
165 Ho J, Dai RZW, Kwong TNY, Wang X, Zhang L, Ip M, Chan R, Hawkey PMK, Lam KLY, Wong MCS, Tse G, Chan MTV, Chan FKL, Yu J, Ng SC, Lee N, Wu JCY, Sung JJY, Wu WKK, Wong SH. Disease Burden of Clostridium difficile Infections in Adults, Hong Kong, China, 2006-2014. Emerg Infect Dis 2017;23:1671-9. [PMID: 28930010 DOI: 10.3201/eid2310.170797] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
166 Gweon TG, Choi MG, Baeg MK, Lim CH, Park JM, Lee IS, Kim SW, Lee DG, Park YJ, Lee JW. Hematologic diseases: High risk of Clostridium difficile associated diarrhea. World J Gastroenterol 2014; 20(21): 6602-6607 [PMID: 24914383 DOI: 10.3748/wjg.v20.i21.6602] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
167 McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018;66:e1-e48. [PMID: 29462280 DOI: 10.1093/cid/cix1085] [Cited by in Crossref: 718] [Cited by in F6Publishing: 613] [Article Influence: 239.3] [Reference Citation Analysis]
168 Kamboj M, Brite J, Aslam A, Kennington J, Babady NE, Calfee D, Furuya Y, Chen D, Augenbraun M, Ostrowsky B, Patel G, Mircescu M, Kak V, Tuma R, Karre TA, Fry DA, Duhaney YP, Moyer A, Mitchell D, Cantu S, Hsieh C, Warren N, Martin S, Willson J, Dickman J, Knight J, Delahanty K, Flood A, Harrington J, Korenstein D, Eagan J, Sepkowitz K. Artificial Differences in Clostridium difficile Infection Rates Associated with Disparity in Testing. Emerg Infect Dis 2018;24:584-7. [PMID: 29460760 DOI: 10.3201/eid2403.170961] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
169 Abdalla AO, Pisipati S, Elnaggar M, Rishi M, Doshi R, Gullapalli N. Outcomes of Clostridioides difficile Infection in Patients With Liver Cirrhosis: A Nationwide Study. Gastroenterology Res 2020;13:53-7. [PMID: 32362963 DOI: 10.14740/gr1240] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
170 Yakob L, Riley TV, Paterson DL, Marquess J, Magalhaes RJ, Furuya-Kanamori L, Clements AC. Mechanisms of hypervirulent Clostridium difficile ribotype 027 displacement of endemic strains: an epidemiological model. Sci Rep 2015;5:12666. [PMID: 26218654 DOI: 10.1038/srep12666] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
171 Lessa FC, Mu Y, Winston LG, Dumyati GK, Farley MM, Beldavs ZG, Kast K, Holzbauer SM, Meek JI, Cohen J, McDonald LC, Fridkin SK. Determinants of Clostridium difficile Infection Incidence Across Diverse United States Geographic Locations. Open Forum Infect Dis 2014;1:ofu048. [PMID: 25734120 DOI: 10.1093/ofid/ofu048] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
172 Cui Y, Dong D, Zhang L, Wang D, Jiang C, Ni Q, Wang C, Mao E, Peng Y. Risk factors for Clostridioides difficile infection and colonization among patients admitted to an intensive care unit in Shanghai, China. BMC Infect Dis 2019;19:961. [PMID: 31711425 DOI: 10.1186/s12879-019-4603-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
173 Bartsch SM, Umscheid CA, Fishman N, Lee BY. Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis. 2013;57:555-561. [PMID: 23704121 DOI: 10.1093/cid/cit346] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 8.4] [Reference Citation Analysis]
174 Hung YP, Lin HJ, Wu TC, Liu HC, Lee JC, Lee CI, Wu YH, Wan L, Tsai PJ, Ko WC. Risk factors of fecal toxigenic or non-toxigenic Clostridium difficile colonization: impact of Toll-like receptor polymorphisms and prior antibiotic exposure. PLoS One 2013;8:e69577. [PMID: 23936050 DOI: 10.1371/journal.pone.0069577] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
175 Quesada-Gómez C, López-Ureña D, Acuña-Amador L, Villalobos-Zúñiga M, Du T, Freire R, Guzmán-Verri C, del Mar Gamboa-Coronado M, Lawley TD, Moreno E, Mulvey MR, de Castro Brito GA, Rodríguez-Cavallini E, Rodríguez C, Chaves-Olarte E. Emergence of an outbreak-associated Clostridium difficile variant with increased virulence. J Clin Microbiol 2015;53:1216-26. [PMID: 25653402 DOI: 10.1128/JCM.03058-14] [Cited by in Crossref: 42] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
176 Crobach MJT, Vernon JJ, Loo VG, Kong LY, Péchiné S, Wilcox MH, Kuijper EJ. Understanding Clostridium difficile Colonization. Clin Microbiol Rev 2018;31:e00021-17. [PMID: 29540433 DOI: 10.1128/CMR.00021-17] [Cited by in Crossref: 86] [Cited by in F6Publishing: 43] [Article Influence: 21.5] [Reference Citation Analysis]
177 Barletta JF, Sclar DA. Use of proton pump inhibitors for the provision of stress ulcer prophylaxis: clinical and economic consequences. Pharmacoeconomics. 2014;32:5-13. [PMID: 24271943 DOI: 10.1007/s40273-013-0119-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
178 Wombwell E, Bransteitter B, Gillen LR. Incidence of Saccharomyces cerevisiae fungemia in hospitalised patients administered Saccharomyces boulardii probiotic. Mycoses 2021;64:1521-6. [PMID: 34585799 DOI: 10.1111/myc.13375] [Reference Citation Analysis]
179 Truong CY, Gombar S, Wilson R, Sundararajan G, Tekic N, Holubar M, Shepard J, Madison A, Tompkins L, Shah N, Deresinski S, Schroeder LF, Banaei N. Real-Time Electronic Tracking of Diarrheal Episodes and Laxative Therapy Enables Verification of Clostridium difficile Clinical Testing Criteria and Reduction of Clostridium difficile Infection Rates. J Clin Microbiol 2017;55:1276-84. [PMID: 28250001 DOI: 10.1128/JCM.02319-16] [Cited by in Crossref: 48] [Cited by in F6Publishing: 23] [Article Influence: 9.6] [Reference Citation Analysis]
180 Cule M, Donnelly P. Stochastic modelling and inference in electronic hospital databases for the spread of infections: Clostridium difficile transmission in Oxfordshire hospitals 2007-2010. Ann Appl Stat 2017;11:655-79. [PMID: 31105805 DOI: 10.1214/16-aoas1011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
181 Flores R, Shi J, Gail MH, Gajer P, Ravel J, Goedert JJ. Assessment of the human faecal microbiota: II. Reproducibility and associations of 16S rRNA pyrosequences. Eur J Clin Invest 2012;42:855-63. [PMID: 22385292 DOI: 10.1111/j.1365-2362.2012.02659.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
182 Valiente E, Bouché L, Hitchen P, Faulds-Pain A, Songane M, Dawson LF, Donahue E, Stabler RA, Panico M, Morris HR, Bajaj-Elliott M, Logan SM, Dell A, Wren BW. Role of Glycosyltransferases Modifying Type B Flagellin of Emerging Hypervirulent Clostridium difficile Lineages and Their Impact on Motility and Biofilm Formation. J Biol Chem 2016;291:25450-61. [PMID: 27703012 DOI: 10.1074/jbc.M116.749523] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
183 Okada Y, Yagihara Y, Wakabayashi Y, Igawa G, Saito R, Higurashi Y, Ikeda M, Tatsuno K, Okugawa S, Moriya K. Epidemiology and virulence-associated genes of Clostridioides difficile isolates and factors associated with toxin EIA results at a university hospital in Japan. Access Microbiol 2020;2:acmi000086. [PMID: 34568752 DOI: 10.1099/acmi.0.000086] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
184 Kim PK, Huh HC, Cohen HW, Feinberg EJ, Ahmad S, Coyle C, Teperman S, Boothe H. Intracolonic vancomycin for severe Clostridium difficile colitis. Surg Infect (Larchmt) 2013;14:532-9. [PMID: 23560732 DOI: 10.1089/sur.2012.158] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
185 Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. Clostridium difficile infection. Nat Rev Dis Primers 2016;2:16020. [PMID: 27158839 DOI: 10.1038/nrdp.2016.20] [Cited by in Crossref: 301] [Cited by in F6Publishing: 241] [Article Influence: 50.2] [Reference Citation Analysis]
186 Kubota H, Makino H, Gawad A, Kushiro A, Ishikawa E, Sakai T, Akiyama T, Matsuda K, Martin R, Knol J, Oishi K. Longitudinal Investigation of Carriage Rates, Counts, and Genotypes of Toxigenic Clostridium difficile in Early Infancy. Appl Environ Microbiol 2016;82:5806-14. [PMID: 27451451 DOI: 10.1128/AEM.01540-16] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
187 Lee CC, Lee JC, Chiu CW, Tsai PJ, Ko WC, Hung YP. Clinical Significance of Toxigenic Clostridioides difficile Growth in Stool Cultures during the Era of Nonculture Methods for the Diagnosis of C. difficile Infection. Microbiol Spectr 2021;9:e0079921. [PMID: 34668727 DOI: 10.1128/Spectrum.00799-21] [Reference Citation Analysis]
188 Na'amnih W, Carmeli Y, Asato V, Goren S, Adler A, Cohen D, Muhsen K. Enhanced Humoral Immune Responses against Toxin A and B of Clostridium difficile is Associated with a Milder Disease Manifestation. J Clin Med 2020;9:E3241. [PMID: 33050453 DOI: 10.3390/jcm9103241] [Reference Citation Analysis]
189 Qiu H, Cassan R, Johnstone D, Han X, Joyee AG, McQuoid M, Masi A, Merluza J, Hrehorak B, Reid R, Kennedy K, Tighe B, Rak C, Leonhardt M, Dupas B, Saward L, Berry JD, Nykiforuk CL. Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model. PLoS One 2016;11:e0157970. [PMID: 27336843 DOI: 10.1371/journal.pone.0157970] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
190 Fuereder T, Koni D, Gleiss A, Kundi M, Makristathis A, Zielinski C, Steininger C. Risk factors for Clostridium difficile infection in hemato-oncological patients: A case control study in 144 patients. Sci Rep 2016;6:31498. [PMID: 27510591 DOI: 10.1038/srep31498] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
191 Dineen SP, Bailey SH, Pham TH, Huerta S. Clostridium difficile enteritis: A report of two cases and systematic literature review. World J Gastrointest Surg 2013; 5(3): 37-42 [PMID: 23556059 DOI: 10.4240/wjgs.v5.i3.37] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
192 Desai K, Gupta SB, Dubberke ER, Prabhu VS, Browne C, Mast TC. Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach. BMC Infect Dis. 2016;16:303. [PMID: 27316794 DOI: 10.1186/s12879-016-1610-3] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 13.7] [Reference Citation Analysis]
193 Sylvester KW, Cheng JW, Mehra MR. Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events. Vasc Health Risk Manag 2013;9:245-54. [PMID: 23696706 DOI: 10.2147/VHRM.S44265] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
194 Ticinesi A, Nouvenne A, Folesani G, Prati B, Morelli I, Guida L, Turroni F, Ventura M, Lauretani F, Maggio M, Meschi T. Multimorbidity in elderly hospitalised patients and risk of Clostridium difficile infection: a retrospective study with the Cumulative Illness Rating Scale (CIRS). BMJ Open 2015;5:e009316. [PMID: 26503394 DOI: 10.1136/bmjopen-2015-009316] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
195 Ali M, Ananthakrishnan AN, Ahmad S, Kumar N, Kumar G, Saeian K. Clostridium difficile infection in hospitalized liver transplant patients: a nationwide analysis. Liver Transpl. 2012;18:972-978. [PMID: 22505356 DOI: 10.1002/lt.23449] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.2] [Reference Citation Analysis]
196 Miller AC, Segre AM, Pemmaraju SV, Sewell DK, Polgreen PM. Association of Household Exposure to Primary Clostridioides difficile Infection With Secondary Infection in Family Members. JAMA Netw Open 2020;3:e208925. [PMID: 32589232 DOI: 10.1001/jamanetworkopen.2020.8925] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
197 Chaudhry R, Sharma N, Gupta N, Kant K, Bahadur T, Shende TM, Kumar L, Kabra SK. Nagging Presence of Clostridium difficile Associated Diarrhoea in North India. J Clin Diagn Res 2017;11:DC06-9. [PMID: 29207702 DOI: 10.7860/JCDR/2017/29096.10592] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
198 Walsh TL, Chan L, Konopka CI, Burkitt MJ, Moffa MA, Bremmer DN, Murillo MA, Watson C, Chan-Tompkins NH. Appropriateness of antibiotic management of uncomplicated skin and soft tissue infections in hospitalized adult patients. BMC Infect Dis 2016;16:721. [PMID: 27899072 DOI: 10.1186/s12879-016-2067-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
199 Lai YH, Tsai BY, Hsu CY, Chen YH, Chou PH, Chen YL, Liu HC, Ko WC, Tsai PJ, Hung YP. The Role of Toll-Like Receptor-2 in Clostridioides difficile Infection: Evidence From a Mouse Model and Clinical Patients. Front Immunol 2021;12:691039. [PMID: 34322122 DOI: 10.3389/fimmu.2021.691039] [Reference Citation Analysis]
200 Barletta JF, Sclar DA. Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients. Crit Care. 2014;18:714. [PMID: 25540023 DOI: 10.1186/s13054-014-0714-7] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 7.6] [Reference Citation Analysis]
201 Amjad W, Qureshi W, Malik A, Singh R, Jafri SM. The outcomes of Clostridioides difficile infection in inpatient liver transplant population. Transpl Infect Dis 2021;:e13750. [PMID: 34695277 DOI: 10.1111/tid.13750] [Reference Citation Analysis]
202 Cowman K, Chen V, Guo Y, Nori P. Using Technology to Enhance Antimicrobial Stewardship Impact in the Acute Care Setting. Curr Treat Options Infect Dis 2020;12:145-57. [DOI: 10.1007/s40506-020-00218-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
203 Alasmari F, Seiler SM, Hink T, Burnham CA, Dubberke ER. Prevalence and risk factors for asymptomatic Clostridium difficile carriage. Clin Infect Dis 2014;59:216-22. [PMID: 24755858 DOI: 10.1093/cid/ciu258] [Cited by in Crossref: 113] [Cited by in F6Publishing: 100] [Article Influence: 14.1] [Reference Citation Analysis]
204 Shen A. Clostridioides difficile Spores: Bile Acid Sensors and Trojan Horses of Transmission. Clin Colon Rectal Surg 2020;33:58-66. [PMID: 32104157 DOI: 10.1055/s-0040-1701230] [Reference Citation Analysis]
205 Eyre DW, Fawley WN, Rajgopal A, Settle C, Mortimer K, Goldenberg SD, Dawson S, Crook DW, Peto TEA, Walker AS, Wilcox MH. Comparison of Control of Clostridium difficile Infection in Six English Hospitals Using Whole-Genome Sequencing. Clin Infect Dis 2017;65:433-41. [PMID: 28575285 DOI: 10.1093/cid/cix338] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
206 Dolan RD, Abougergi MS, Schulman AR. Morbid Obesity Increases 30-Day Readmission and Morbidity in Clostridiodes difficile Infection. Obes Surg 2021;31:2168-73. [PMID: 33544330 DOI: 10.1007/s11695-021-05245-9] [Reference Citation Analysis]
207 Jump RL. Clostridium difficile infection in older adults. Aging health 2013;9:403-14. [PMID: 24955106 DOI: 10.2217/ahe.13.37] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
208 Swiatek PR, Johnson SP, Wang L, Liu M, Chung TT, Chung KC. Effect of Posthospital Syndrome on Health Care Utilization After Abdominal Contouring Surgery. Ann Plast Surg 2018;81:e4-e11. [PMID: 30211741 DOI: 10.1097/SAP.0000000000001613] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
209 LaSala PR, Ekhmimi T, Hill AK, Farooqi I, Perrotta PL. Quantitative fecal lactoferrin in toxin-positive and toxin-negative Clostridium difficile specimens. J Clin Microbiol 2013;51:311-3. [PMID: 23135940 DOI: 10.1128/JCM.02735-12] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
210 Cojocariu C, Girleanu I, Trifan A, Olteanu A, Muzica CM, Huiban L, Chiriac S, Singeap AM, Cuciureanu T, Sfarti C, Stanciu C. Did the severe acute respiratory syndrome-coronavirus 2 pandemic cause an endemic Clostridium difficile infection? World J Clin Cases 2021; 9(33): 10180-10188 [PMID: 34904088 DOI: 10.12998/wjcc.v9.i33.10180] [Reference Citation Analysis]
211 Gilca R, Fortin E, Frenette C, Longtin Y, Gourdeau M. Seasonal variations in Clostridium difficile infections are associated with influenza and respiratory syncytial virus activity independently of antibiotic prescriptions: a time series analysis in Quebec, Canada. Antimicrob Agents Chemother 2012;56:639-46. [PMID: 22106208 DOI: 10.1128/AAC.05411-11] [Cited by in Crossref: 40] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
212 Schäffler H, Breitrück A. Clostridium difficile - From Colonization to Infection. Front Microbiol 2018;9:646. [PMID: 29692762 DOI: 10.3389/fmicb.2018.00646] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 13.8] [Reference Citation Analysis]
213 Yakob L, Riley TV, Paterson DL, Marquess J, Clements AC. Assessing control bundles for Clostridium difficile: a review and mathematical model. Emerg Microbes Infect 2014;3:e43. [PMID: 26038744 DOI: 10.1038/emi.2014.43] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
214 Curry SR, Muto CA, Schlackman JL, Pasculle AW, Shutt KA, Marsh JW, Harrison LH. Use of multilocus variable number of tandem repeats analysis genotyping to determine the role of asymptomatic carriers in Clostridium difficile transmission. Clin Infect Dis 2013;57:1094-102. [PMID: 23881150 DOI: 10.1093/cid/cit475] [Cited by in Crossref: 151] [Cited by in F6Publishing: 137] [Article Influence: 16.8] [Reference Citation Analysis]
215 Kong LY, Eyre DW, Corbeil J, Raymond F, Walker AS, Wilcox MH, Crook DW, Michaud S, Toye B, Frost E, Dendukuri N, Schiller I, Bourgault AM, Dascal A, Oughton M, Longtin Y, Poirier L, Brassard P, Turgeon N, Gilca R, Loo VG. Clostridium difficile: Investigating Transmission Patterns Between Infected and Colonized Patients Using Whole Genome Sequencing. Clin Infect Dis 2019;68:204-9. [PMID: 29846557 DOI: 10.1093/cid/ciy457] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
216 Yakob L, Riley TV, Paterson DL, Clements AC. Clostridium difficile exposure as an insidious source of infection in healthcare settings: an epidemiological model. BMC Infect Dis 2013;13:376. [PMID: 23947736 DOI: 10.1186/1471-2334-13-376] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
217 Skoutelis A, Pefanis A, Tsiodras S, Sipsas NV, Lelekis M, Lazanas MC, Gargalianos P, Dalekos GN, Roilides E, Samonis G, Maltezos E, Hatzigeorgiou D, Lada M, Metallidis S, Stoupis A, Chrysos G, Karnesis L, Symbardi S, Loupa CV, Giamarellou H, Kioumis I, Sambatakou H, Tsianos E, Kotsopoulou M, Georgopali A, Liakou K, Perlorentzou S, Levidiotou S, Giotsa-Toutouza M, Tsorlini-Christoforidou H, Karaiskos I, Kouppari G, Trikka-Graphakos E, Ntrivala MA, Themeli-Digalaki K, Pangalis A, Kachrimanidou M, Martsoukou M, Karapsias S, Panopoulou M, Maraki S, Orfanou A, Petinaki E, Orfanidou M, Baka V, Stylianakis A, Spiliopoulou I, Smilakou S, Zerva L, Vogiatzakis E, Belesiotou E, Gogos CA. Point-prevalence survey of healthcare facility-onset healthcare-associated Clostridium difficile infection in Greek hospitals outside the intensive care unit: The C. DEFINE study. PLoS One 2017;12:e0182799. [PMID: 28813492 DOI: 10.1371/journal.pone.0182799] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
218 Elias E, Targownik LE. The Clinician's Guide to Proton Pump Inhibitor Related Adverse Events. Drugs 2019;79:715-31. [PMID: 30972661 DOI: 10.1007/s40265-019-01110-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
219 Moehring RW, Lofgren ET, Anderson DJ. Impact of change to molecular testing for Clostridium difficile infection on healthcare facility-associated incidence rates. Infect Control Hosp Epidemiol 2013;34:1055-61. [PMID: 24018922 DOI: 10.1086/673144] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 5.3] [Reference Citation Analysis]
220 Brunetti G, Giuliani A, Navazio AS, Paradisi C, Raponi F, Conti LA, Raponi G. Candida gut colonization, yeast species distribution, and biofilm production in Clostridioides difficile infected patients: a comparison between three populations in two different time periods. Braz J Microbiol 2021. [PMID: 34264501 DOI: 10.1007/s42770-021-00512-4] [Reference Citation Analysis]
221 Kalluru S, Eggers S, Barker A, Shirley D, Sethi AK, Sengupta S, Yeptho K, Safdar N. Risk factors for infection with multidrug-resistant organisms in Haryana, India. Am J Infect Control 2018;46:341-5. [PMID: 29102426 DOI: 10.1016/j.ajic.2017.08.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
222 Zheng Y, Luo Y, Lv Y, Huang C, Sheng Q, Zhao P, Ye J, Jiang W, Liu L, Song X, Tong Z, Chen W, Lin J, Tang YW, Jin D, Fang W. Clostridium difficile colonization in preoperative colorectal cancer patients. Oncotarget 2017;8:11877-86. [PMID: 28060753 DOI: 10.18632/oncotarget.14424] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
223 Wagner M, Lavoie L, Goetghebeur M. Clinical and economic consequences of vancomycin and fidaxomicin for the treatment of Clostridium difficile infection in Canada. Can J Infect Dis Med Microbiol 2014;25:87-94. [PMID: 24855476 DOI: 10.1155/2014/793532] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
224 Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol 2012;5:219-32. [PMID: 22778788 DOI: 10.1177/1756283X12437358] [Cited by in Crossref: 149] [Cited by in F6Publishing: 68] [Article Influence: 14.9] [Reference Citation Analysis]
225 Bibbò S, Lopetuso LR, Ianiro G, Di Rienzo T, Gasbarrini A, Cammarota G. Role of microbiota and innate immunity in recurrent Clostridium difficile infection. J Immunol Res 2014;2014:462740. [PMID: 24995345 DOI: 10.1155/2014/462740] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
226 Dharmarajan K, Krumholz HM. Strategies to Reduce 30-Day Readmissions in Older Patients Hospitalized with Heart Failure and Acute Myocardial Infarction. Curr Geriatr Rep 2014;3:306-15. [PMID: 25431752 DOI: 10.1007/s13670-014-0103-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
227 Saab S, Alper T, Sernas E, Pruthi P, Alper MA, Sundaram V. Hospitalized Patients with Cirrhosis Should Be Screened for Clostridium difficile Colitis. Dig Dis Sci 2015;60:3124-9. [DOI: 10.1007/s10620-015-3707-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
228 Permpalung N, Upala S, Sanguankeo A, Sornprom S. Association between NSAIDs and Clostridium difficile-Associated Diarrhea: A Systematic Review and Meta-Analysis. Can J Gastroenterol Hepatol 2016;2016:7431838. [PMID: 27446866 DOI: 10.1155/2016/7431838] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
229 Conlon-Bingham G, Aldeyab M, Kearney MP, Scott MG, Baldwin N, McElnay JC. Reduction in the incidence of hospital-acquired MRSA following the introduction of a chlorine dioxide 275 ppm based disinfecting agent in a district general hospital. Eur J Hosp Pharm 2016;23:28-32. [PMID: 31156810 DOI: 10.1136/ejhpharm-2014-000608] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
230 Olsen MA, Stwalley D, Demont C, Dubberke ER. Increasing Age Has Limited Impact on Risk of Clostridium difficile Infection in an Elderly Population. Open Forum Infect Dis 2018;5:ofy160. [PMID: 30046643 DOI: 10.1093/ofid/ofy160] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
231 Burnham CA, Carroll KC. Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin Microbiol Rev. 2013;26:604-630. [PMID: 23824374 DOI: 10.1128/cmr.00016-13] [Cited by in Crossref: 248] [Cited by in F6Publishing: 120] [Article Influence: 31.0] [Reference Citation Analysis]
232 Vincent C, Stephens DA, Loo VG, Edens TJ, Behr MA, Dewar K, Manges AR. Reductions in intestinal Clostridiales precede the development of nosocomial Clostridium difficile infection. Microbiome. 2013;1:18. [PMID: 24450844 DOI: 10.1186/2049-2618-1-18] [Cited by in Crossref: 81] [Cited by in F6Publishing: 71] [Article Influence: 9.0] [Reference Citation Analysis]
233 He T, Kaplan SE, Gomez LA, Lu X, Ramanathan LV, Kamboj M, Tang YW. Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection. Eur J Clin Microbiol Infect Dis 2018;37:2341-6. [PMID: 30242543 DOI: 10.1007/s10096-018-3381-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
234 El Feghaly RE, Stauber JL, Tarr PI, Haslam DB. Intestinal inflammatory biomarkers and outcome in pediatric Clostridium difficile infections. J Pediatr 2013;163:1697-1704.e2. [PMID: 24011765 DOI: 10.1016/j.jpeds.2013.07.029] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 5.0] [Reference Citation Analysis]
235 Mills JP, Rao K, Young VB. Probiotics for prevention of Clostridium difficile infection. Curr Opin Gastroenterol 2018;34:3-10. [PMID: 29189354 DOI: 10.1097/MOG.0000000000000410] [Cited by in Crossref: 51] [Cited by in F6Publishing: 26] [Article Influence: 12.8] [Reference Citation Analysis]
236 Simmering JE, Polgreen LA, Campbell DR, Cavanaugh JE, Polgreen PM. Hospital Transfer Network Structure as a Risk Factor for Clostridium difficile Infection. Infect Control Hosp Epidemiol 2015;36:1031-7. [PMID: 26072907 DOI: 10.1017/ice.2015.130] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
237 McLure A, Glass K. Some simple rules for estimating reproduction numbers in the presence of reservoir exposure or imported cases. Theor Popul Biol 2020;134:182-94. [PMID: 32304644 DOI: 10.1016/j.tpb.2020.04.002] [Reference Citation Analysis]
238 Mao EJ, Kelly CR, Machan JT. Racial Differences in Clostridium difficile Infection Rates Are Attributable to Disparities in Health Care Access. Antimicrob Agents Chemother 2015;59:6283-7. [PMID: 26248363 DOI: 10.1128/AAC.00795-15] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
239 Fettucciari K, Marconi P, Marchegiani A, Fruganti A, Spaterna A, Bassotti G. Invisible steps for a global endemy: molecular strategies adopted by Clostridioides difficile. Therap Adv Gastroenterol 2021;14:17562848211032797. [PMID: 34413901 DOI: 10.1177/17562848211032797] [Reference Citation Analysis]
240 Miller LG, Daum RS, Creech CB, Young D, Downing MD, Eells SJ, Pettibone S, Hoagland RJ, Chambers HF; DMID 07-0051 Team. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. N Engl J Med 2015;372:1093-103. [PMID: 25785967 DOI: 10.1056/NEJMoa1403789] [Cited by in Crossref: 110] [Cited by in F6Publishing: 34] [Article Influence: 15.7] [Reference Citation Analysis]
241 Usacheva EA, Jin JP, Peterson LR. Host response to Clostridium difficile infection: Diagnostics and detection. J Glob Antimicrob Resist 2016;7:93-101. [PMID: 27693863 DOI: 10.1016/j.jgar.2016.08.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
242 Pappas M, Jolly S, Vijan S. Defining Appropriate Use of Proton-Pump Inhibitors Among Medical Inpatients. J Gen Intern Med. 2016;31:364-371. [PMID: 26553337 DOI: 10.1007/s11606-015-3536-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
243 Freedberg DE, Zhou MJ, Cohen ME, Annavajhala MK, Khan S, Moscoso DI, Brooks C, Whittier S, Chong DH, Uhlemann AC, Abrams JA. Pathogen colonization of the gastrointestinal microbiome at intensive care unit admission and risk for subsequent death or infection. Intensive Care Med 2018;44:1203-11. [PMID: 29936583 DOI: 10.1007/s00134-018-5268-8] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 12.8] [Reference Citation Analysis]
244 Dharmarajan K, Hsieh AF, Lin Z, Bueno H, Ross JS, Horwitz LI, Barreto-Filho JA, Kim N, Bernheim SM, Suter LG. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA. 2013;309:355-363. [PMID: 23340637 DOI: 10.1001/jama.2012.216476] [Cited by in Crossref: 612] [Cited by in F6Publishing: 559] [Article Influence: 68.0] [Reference Citation Analysis]
245 Dharmarajan K, Hsieh AF, Kulkarni VT, Lin Z, Ross JS, Horwitz LI, Kim N, Suter LG, Lin H, Normand SL, Krumholz HM. Trajectories of risk after hospitalization for heart failure, acute myocardial infarction, or pneumonia: retrospective cohort study. BMJ 2015;350:h411. [PMID: 25656852 DOI: 10.1136/bmj.h411] [Cited by in Crossref: 113] [Cited by in F6Publishing: 104] [Article Influence: 16.1] [Reference Citation Analysis]
246 Donskey CJ, Sunkesula VC, Jencson AL, Stone ND, Gould CV, McDonald LC, Samore M, Mayer J, Pacheco S, Sambol S, Petrella L, Terry D, Gerding DN. Utility of a commercial PCR assay and a clinical prediction rule for detection of toxigenic Clostridium difficile in asymptomatic carriers. J Clin Microbiol 2014;52:315-8. [PMID: 24153132 DOI: 10.1128/JCM.01852-13] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
247 Lübbert C, John E, von Müller L. Clostridium difficile infection: guideline-based diagnosis and treatment. Dtsch Arztebl Int. 2014;111:723-731. [PMID: 25404529 DOI: 10.3238/arztebl.2014.0723] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
248 Half E, Arber N. Chemoprevention of gastrointestinal neoplasia. Curr Gastroenterol Rep 2013;15:320. [PMID: 23605648 DOI: 10.1007/s11894-013-0320-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
249 Schlaberg R, Barrett A, Edes K, Graves M, Paul L, Rychert J, Lopansri BK, Leung DT. Fecal Host Transcriptomics for Non-Invasive Human Mucosal Immune Profiling: Proof of Concept in Clostridium Difficile Infection. Pathog Immun 2018;3:164-80. [PMID: 30283823 DOI: 10.20411/pai.v3i2.250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
250 Angione SL, Sarma AA, Novikov A, Seward L, Fieber JH, Mermel LA, Tripathi A. A novel subtyping assay for detection of Clostridium difficile virulence genes. J Mol Diagn 2014;16:244-52. [PMID: 24434086 DOI: 10.1016/j.jmoldx.2013.11.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
251 Wang X, Cai L, Yu R, Huang W, Zong Z. ICU-Onset Clostridium difficile infection in a university hospital in China: a prospective cohort study. PLoS One 2014;9:e111735. [PMID: 25372033 DOI: 10.1371/journal.pone.0111735] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
252 Cózar-Llistó A, Ramos-Martinez A, Cobo J. Clostridium difficile Infection in Special High-Risk Populations. Infect Dis Ther 2016;5:253-69. [PMID: 27515721 DOI: 10.1007/s40121-016-0124-z] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
253 Kamboj M, Gennarelli RL, Brite J, Sepkowitz K, Lipitz-Snyderman A. Risk for Clostridiodes difficile Infection among Older Adults with Cancer. Emerg Infect Dis 2019;25. [PMID: 31442017 DOI: 10.3201/eid2509.181142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]